Zobrazeno 1 - 4
of 4
pro vyhledávání: '"59"'
Autor:
Jonas Paludo, Yi Lin, Allison C. Rosenthal, Jose C. Villasboas, Mohamed A. Kharfan-Dabaja, Javier Munoz, Hemant S. Murthy, Radhika Bansal, Stephen M. Ansell, Madiha Iqbal, Thomas E. Witzig, Matthew J. Maurer, Matthew A. Hathcock, Yucai Wang, Grzegorz S. Nowakowski, Patrick B. Johnston, Arushi Khurana, Nora N Bennani, Januario E. Castro, Evandro D. Bezerra
Publikováno v:
Transplantation and Cellular Therapy. 28:S418-S419
Background Patients (pts) with aggressive B-cell non-Hodgkin lymphoma (NHL) progressing after anti-CD19 chimeric antigen receptor T (CART) cell therapy have poor prognosis and may benefit from new therapy options through clinical trials. However, in
Autor:
David Marin, Qaiser Bashir, Chitra Hosing, Samer A. Srour, Jeremy Ramdial, Jin S. Im, Alison M. Gulbis, Uday R. Popat, Marina Konopleva, Borje S. Andersson, Richard E. Champlin, Partow Kebriaei, Yago Nieto, Muzaffar H. Qazilbash, Gheath Alatrash, Rohtesh S. Mehta, Amanda Olson, Betul Oran, Amin M. Alousi, Neeraj Saini, Tapan M. Kadia, Elizabeth J. Shpall, Roland L. Bassett, Katayoun Rezvani, Benigno C. Valdez
Publikováno v:
Transplantation and Cellular Therapy. 28:S82-S83
Background: Myeloablative conditioning can be given safely to older patients by simply administering busulfan over a longer period (fractionated busulfan regimen) than the standard four-day regimen (Popat et al Lancet Haematology 2018). This longer d
Autor:
Justin Kline, Andrzej Jakubowiak, Michael R. Bishop, Todd M. Zimmerman, Cara A. Rosenbaum, Koen van Besien, Rebecca Malloy, Amittha Wickrema, Gottfried von Keudell
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 14:S150-S152
Although autologous stem cell transplantation (ASCT) is effective for patients with multiple myeloma (MM), disease relapse remains problematic. Despite significant advances in therapeutics for MM, it remains mostly incurable. Following ASCT, a majori
Autor:
Carlos Fernández de Larrea, Joan Bladé, María Teresa Cibeira, Tania Díaz, Mariano Monzo, Laura Rosiñol, Alfons Navarro, Dolors Fuster, Natalia Tovar
Publikováno v:
Leukemia Research. 35:1178-1183
Abstract 4041 Background: Thalidomide was the first of the so-called new drugs incorporated in the treatment of multiple myeloma (MM). In this era of emerging novel agents, there is a real need for increased knowledge of the pre-treatment genetic pro